Alan L. Rubino joined Emisphere in 2012 as President and Chief Executive Officer. Upon joining, he was also appointed as Class II Director of the Company. Mr. Rubino’s career spans over 30 years at every level of the biopharmaceutical industry.
Previously, he was President and CEO of New American Therapeutics Inc., a private specialty pharmaceutical company that acquired, marketed and developed therapeutic products and achieved major success through the acquisition, marketing, and eventual sale of its herpes labialis drug, Denavir® where the team tripled sales in 18 months and sold then sold the asset to Renaissance Pharmaceuticals, for a multiple of three times sales. Mr. Rubino served before New American Therapeutics, Inc. as the CEO and President of Akrimax Pharmaceuticals, where he and team acquired Tirosint® and NitroMist®, two key NDA approved launch products. Rounding out his background, he had also been President and COO of another publicly-held entity, Pharmos Corporation, where he led the transformation of the company through the acquisition of Vela Pharmaceuticals. Mr. Rubino also spent four years in senior leadership positions on the strategic services side of the healthcare sector with two other public companies, Cardinal Health and PDI Inc.
A major portion of Mr. Rubino’s highly successful career includes his twenty-four years spent at Hoffmann-La Roche, now Genentech (a subsidiary of Roche) which remains one of the world’s top 10 biopharmaceutical companies. At Roche, he was a corporate officer and member of the U.S. Executive Committee. He held a variety of key senior executive positions that encompassed business operations, business strategy, human resources, marketing, sales, corporate development and strategic planning.
Mr. Rubino currently serves on the Corporate Boards of Aastrom Biosciences, Genisphere, Inc. and Sanuwave Health, Inc. For the past 17 years, he has served on the Board of Rutgers University School of Business and the Lerner Center for Pharmaceutical Studies. Mr. Rubino holds a B.A. in economics from Rutgers University along with a full minor in biology and chemistry. He also attended multiple executive education courses at Harvard Business School and the University of Lausanne in Switzerland.
Carl V. Sailer joined Emisphere October 2012 as Vice President of Sales and Marketing. Mr. Sailer’s career spans over twenty years in the pharmaceutical industry. Prior to joining Emisphere, Mr. Sailer was the Vice President of Product Commercialization at New American Therapeutics where he developed and managed the start-up company’s commercial and analytics infrastructure to market inline brands and assess products for acquisition. After a very successful venture, the company ultimately sold Denavir®, a topical treatment for HSV-1, for a significant return for investors.
Previously, Mr. Sailer was the Vice President of Product Commercialization and a member of the Executive Committee at PDI, Inc. Mr. Sailer led a business unit which fully funded and managed the marketing and selling of pharmaceutical products in exchange for a commensurate share of revenue. During his tenure at PDI, Mr. Sailer held leadership positions in marketing, business development and product development.
During his prior ten years in the industry, Mr. Sailer held sales, sales leadership and marketing positions of increasing responsibility in the pharmaceutical and ethical OTC marketplaces with Bristol-Myers Squibb and Bayer Healthcare.
Mr. Sailer holds a Master of Business Administration from Hofstra University and completed his undergraduate work at Seton Hall University where he earned a Bachelor of Science in marketing with a minor in journalism.
M. Gary I. Riley, DVM, Ph.D., Vice President, Nonclinical Development and Applied Biology, joined Emisphere in October 2007. Dr. Riley is a graduate veterinarian with degrees from Sydney University and Melbourne University and was awarded a Ph.D. in Comparative Pathology from the University of Missouri, Columbia. He was Associate Professor of Veterinary Pathology at Iowa State University before entering the private sector. Previously, Dr. Riley was the Vice President of Toxicology and Applied Biology at Alkermes, Inc. and Director of Pathobiology at Lederle Laboratories. Dr. Riley is certified by the American College of Veterinary Pathologists and the American Board of Toxicology. His professional contributions include over 50 scientific publications and preclinical submissions to the U.S. FDA and EU drug registration agencies.
As Emisphere’s Lead Chemist, Dr. Gschneidner is responsible for developing a better understanding of the Eligen® Technology. Dr. Gschneidner joined Emisphere in 1996 as a Medicinal Chemist and over the years has been involved in the design, synthesis, scale-up and manufacture of Emisphere carriers. Other responsibilities have included overseeing carrier screening and serving as a technical liaison to Emisphere’s partners. Previously, Dr. Gschneidner worked as research scientist at Cytec and as a post-doctoral fellow at the University of Colorado, Boulder.
Dr. Gschneidner holds a Ph.D. in Organic Chemistry from University of Wisconsin, Madison and a Bachelor of Science in Chemistry from Iowa State University. Dr. Gschneidner has authored a number of scientific communications, including peer reviewed scientific publications and national conference presentations. He is an inventor on twenty-four U.S. patents.
Dr. De Lecea joined Emisphere as Global Head of Business Development in February of 2013. His career spans over 25 years at every level of the biopharmaceutical industry.
Most recently, he was Vice President of International & Business development at Grupo Ferrer International, where he and his team presided over a successful venture that was focused on the acquisition, marketing, and commercialization of proprietary and in-licensed products. A major portion of Dr. De Lecea's highly successful career includes the transformation of an essentially domestic business of the Group into a broad international operation, including the creation from scratch of over a dozen new affiliates; and established a new network of joint-ventures, licensing and distribution agreements across 93 countries in the world. During his tenure at Ferrer, Dr. de Lecea set up Ferrer's international commercial infrastructure, all sales and marketing activities for Ferrer's product portfolio and oversaw management of all worldwide business development initiatives. Dr. De Lecea led many key top level executive initiatives and presided over numerous commercial product launches across a spectrum of therapeutic areas including orphan drugs; hospital products; Rx products in the CNS, cardiovascular, gastro and derma fields; OTCs; medical devices and diagnostics.
Dr. De Lecea currently serves as a member of the Board of Directors of Aurum Biosciences, CEO of Lemus Buhils SL, and as Advisor to the Board at Kinesis Consulting, Recerca Clinica and AB Biotics. Dr. De Lecea is Certified by IESE Business School in the Management of Health Care Institutions. He also followed IESE’s PADE one of the most prestigious executive education management courses in the world. Dr. de Lecea is MD and Specialist in Anesthesiology and Critical Care from the University of Barcelona, Spain and is licensed to practice. He was also trained in Endocrinology in the EU.